Skip to main content

Table 1 Sample size calculations and magnitude of difference in left ventricular remodeling between treatment groups

From: Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101 - Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI

Placebo

Δ LVEDV

at 1 year

Perindopril

Δ LVEDV

at 1 year

% Remodeling prevented

+11%

+1%

90%

+11.7%

+1.9%

84%

+12.5%

+2.75%

78%

+14.2%

+4.4%

69%

+15.8%

+6.1%

62%